New guidelines on migraine prevention reflect increasing options for patients
Reported bySTAT News ↗·Sourced by Goodlede
Updated guidelines released by the American Headache Society and American Academy of Neurology—their first update since 2012—recommend preventive treatment for people with four or more migraine days per month, reflecting at least six new FDA-approved medications including CGRP-targeting therapies like atogepant, eptinezumab, and erenumab.
Guidelines recommend preventive treatment but do not guarantee access or insurance coverage.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at STAT News
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede